HHorinouchi· @HHorinouchi · X·· 2 days agoScore60
Body · original
🆙#ESMO26 Proffered Paper: #LCSM Non-Mets 🔥PEARLS/KEYNOTE-091: Final Analysis of Adjuvant Pembrolizumab (Pembro) in Resected Early-Stage Non–Small-Cell Lung Cancer (NSCLC): Phase 3 Study 🎙️ @drMaryOBr 🔢2511O 🎯Consistent DFS Benefit (HR 0.85, 58.7 vs 43.3mo; n=1177) 🎯6-Yr OS 68.5% vs 66.4% (HR 0.98, NS) 🎯Favorable LCSS Trend (HR 0.81) ☑️NCT02504372 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC
Heat 4 · 3 likes · 0 replies · 1 repost
Conference abstracts
NCT02504372NCT02504372matched by - **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
- **标题 / Title：** Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)Read the abstract →Source: HHorinouchi · x.com